CVS Health® is committed to promoting the use of high-quality, cost-effective medications, including biosimilar drugs. These drugs are essential for patients who require treatment for chronic and severe conditions. They can be used to treat a wide range of conditions, from certain types of cancer to diabetes, and they represent a significant opportunity for managing drug costs within the healthcare system.
Recent research has highlighted the benefits of biosimilar drugs in making treatments more affordable. Dr. Sree Chaguturu, Executive Vice President and Chief Medical Officer at CVS Health, has written a report that discusses this topic in detail. The report also examines the role of Cordavis™, a CVS Health subsidiary that specializes in producing high-quality biosimilars, in improving patient access to these life-changing treatments and driving innovation in healthcare.
The impact of biosimilar drugs on healthcare is significant. By offering an alternative to expensive branded medications, they make treatments more accessible and affordable for patients. This is particularly important for those with chronic or severe health conditions who may need ongoing treatment.
In addition to their affordability benefits, biosimilar drugs have also been shown to be effective in treating various health conditions. For example, they can be used to treat certain types of cancer or diabetes just as effectively as branded medications but at a much lower cost. This makes them an attractive option for both patients and healthcare providers alike.
To learn more about the impact of biosimilar drugs and how they are making healthcare more accessible, you can read the full report (PDF) authored by Dr. Sree Chaguturu on our website today!
